The estimated Net Worth of Arie Belldegrun is at least $22 Million dollars as of 16 May 2024. Arie Belldegrun owns over 1,724,137 units of Allogene Therapeutics Inc stock worth over $5,017,239 and over the last 8 years he sold ALLO stock worth over $9,644,658. In addition, he makes $7,316,720 as Executive Chairman of the Board at Allogene Therapeutics Inc.
Sign up
Arie Belldegrun ALLO stock SEC Form 4 insiders trading
Arie has made over 14 trades of the Allogene Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,724,137 units of ALLO stock worth $4,999,997 on 16 May 2024.
The largest trade he's ever made was buying 1,724,137 units of Allogene Therapeutics Inc stock on 16 May 2024 worth over $4,999,997. On average, Arie trades about 76,332 units every 73 days since 2016. As of 16 May 2024 he still owns at least 1,724,137 units of Allogene Therapeutics Inc stock.
You can see the complete history of Arie Belldegrun stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arie Belldegrun biography
Dr. Arie S. Belldegrun M.D. serves as Executive Chairman of the Board of the Company. From March 2014 until October 2017 Dr. Belldegrun served as the President and Chief Executive Officer of Kite and as a director from June 2009 until October 2017. Dr. Belldegrun currently serves as Chairman of Urogen Pharma, Ltd., a position he has held since December 2012, as Chairman and Partner of Two River Consulting, LLC, a position he has held since June 2009, as Chairman of the Board of Directors of Kronos Bio, Inc., a position that he has held since June 2017, as a director of Breakthrough Properties LLC and Breakthrough Services LLC, a position he has held since April 2019, and as a director of ByHeart, Inc., a position he has held since October 2019. Dr. Belldegrun has also served as Senior Managing Director of Vida Ventures, LLC since November 2017. Dr. Belldegrun previously served as a director of Teva Pharmaceutical Industries Ltd. from March 2013 until January 2017, Chairman of Arno Therapeutics, Inc. from March 2008 until January 2017, a director of Capricor Therapeutics, Inc. from September 2009 until November 2013, and a director of SonaCare Medical, LLC from October 2009 until October 2014. In 1996, he founded Agensys, Inc., a biotechnology company, where he served as its founding Chairman from 1996 to 2001, and continued to serve on the board until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009, when it was acquired by Johnson & Johnson. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.
What is the salary of Arie Belldegrun?
As the Executive Chairman of the Board of Allogene Therapeutics Inc, the total compensation of Arie Belldegrun at Allogene Therapeutics Inc is $7,316,720. There are 2 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
What's Arie Belldegrun's mailing address?
Arie's mailing address filed with the SEC is 400 ALEXANDER PARK DRIVE, , PRINCETON, NJ, 08540.
Insiders trading at Allogene Therapeutics Inc
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun, and Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
What does Allogene Therapeutics Inc do?
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
What does Allogene Therapeutics Inc's logo look like?
Complete history of Arie Belldegrun stock trades at UroGen Pharma Ltd, Allogene Therapeutics Inc, and Kronos Bio
Allogene Therapeutics Inc executives and stock owners
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Chang,
President, Chief Executive Officer, Co-Founder, Director -
Rafael Amado,
Executive Vice President - Research and Development, Chief Medical Officer -
Arie Belldegrun,
Executive Chairman of the Board -
Eric Schmidt,
Chief Financial Officer -
Alison Moore,
Chief Technical Officer -
Dr. David D. Chang M.D., Ph.D.,
Co-Founder, Pres, CEO & Director -
Joshua Kazam,
Co-Founder, Director -
Dr. Rafael G. Amado M.D.,
Exec. VP of R&D -
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.,
Co-Founder & Exec. Chairman -
Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS,
Co-Founder & Exec. Chairman -
Dr. Rafael G. Amado,
Chief Medical Officer and Exec. VP of R&D -
Dr. Alison Moore Ph.D.,
Chief Technical Officer -
Dr. Eric Thomas Schmidt Ph.D.,
Chief Financial Officer -
Veer Bhavnagri,
Gen. Counsel & Compliance Officer -
Franz Humer,
Independent Director -
Deborah Messemer,
Independent Director -
Owen Witte,
Independent Director -
Joshua A. Kazam,
Co-Founder & Director -
Veer Bhavnagri,
Chief Compliance Officer, General Counsel -
Todd Sisitsky,
Independent Director -
John DeYoung,
Independent Director -
David Bonderman,
Lead Independent Director -
Stephen Cheng,
Chief Information Officer -
David M. Tanen J.D.,
Sec. -
Christine Cassiano,
Chief Communications Officer -
Barbra Sasu,
Chief Scientific Officer -
Timothy L. Moore,
Chief Technical Officer -
Yinlin Jack Chen,
SVP, Finance -
Inc Pfizer,
10% owner -
Earl Martin Douglas,
SVP, General Counsel -
Elizabeth A. Barrett,
-
Vicki L Sato,
-
Equity Holdings 2 B.V. Pf,
10% owner -
Stephen Mayo,
-
Zachary Roberts,
EVP of R&D -
Lillian Smith,
VP, Corporate Counsel -
Geoffrey M. Parker,
CHIEF FINANCIAL OFFICER